肝细胞癌癌组织CBX7和PERK表达及其对手术治疗后患者预后的影响*

目的 研究肝细胞癌癌组织色素框同源蛋白7(CBX7)和磷酸化胞外信号调节激酶(PERK)表达及其对术后预后的影响。方法 2016年1月～2017年1月在我院接受治疗的肝细胞癌患者68例,所有患者接受肝癌切除术,并随访3年。术后,取癌组织和癌旁肝组织,采用RT-PCR法检测癌组织和癌旁组织CBX7 mRNA和PERK mRNA水平,采用免疫组化法检测癌组织CBX7和PERK蛋白表达。结果 癌组织CBX7 mRNA水平为(0.51±0.10),显著低于癌旁组织【(4.11±0.91),P<0.05】,而癌组织PERK mRNA水平为(4.87±0.99),显著高于癌旁组织【(0.58±0.15,P<0.05】;38例肿瘤直径>3 cm患者癌组织CBX7蛋白呈高表达阳性率为33.3%,显著低于30例肿瘤直径≤3 cm组的66.7%,而PERK高表达阳性率为73.3%,显著高于肿瘤直径≤3 cm组的26.7%,28例AJCC Ⅲ/Ⅳ期患者癌组织CBX7蛋白呈高表达阳性率为8.3%,显著低于40例AJCC Ⅰ/Ⅱ期患者的91.7%,而PERK高表达阳性率为70.0%,显著高于对照组的30.0%(P<0.05);32例癌组织CBX7高表达患者1 a、2 a和3 a生存率分别为78.1%、65.6%和53.1%,显著高于36例呈低表达患者【分别为52.7%、38.9%和30.6%,P<0.05】,38例癌组织PERK高表达患者1 a、2 a和3 a生存率分别为55.3%、44.7%和31.6%,显著低于30例呈低表达患者【分别为80.0%、63.6%和53.3%,P<0.05】。结论 癌组织CBX7表达下调,而PERK表达增强的HCC患者预后差,需要给予特别的关注。

Expression of CBX7 and PERK incancerous tissues in patients with hepatocellular carcinoma and its implication of prognosis after hepatectomy

Objective The aim of this study was to detect the expression of chromobox protein homolog 7 (CBX7) and phosphorylated extracellular signal-regulated kinase (PERK) in cancerous tissues in patients with hepatocellular carcinoma (HCC) and explore their implications of prognosis after hepatectomy. Methods A total of 68 patients with HCC were treated with hepatectomy in our hospital between January 2016 and January 2017, and the cancerous and adjacent non-cancerous liver tissues were collected. The CBX7 mRNA and PERK mRNA were detected by RT-PCR, and the expression of CBX7 and PERK proteins in cancerous tissues were detected by immunohistochemistry. Results The CBX7 mRNA level in cancerous tissue was significantly lower than that in adjacent liver tissues [(0.51±0.10) vs. (4.11±0.91), P<0.05], while the PERK mRNA level was significantly higher than that in adjacent liver tissues [(4.87±0.99) vs. (0.58±0.15, P<0.05]; the positive rate of intensified expression of CBX7 in 38 patients with tumor diameter >3 cm was 33.3%, significantly lower than 66.7% in 30 patients with tumor size ≤3 cm, while the positive rate of intensified expression of PERK was 73.3%, much higher than 26.7% in patients with tumor size ≤3 cm; the positive rate of intensified expression of CBXY in 28 patients with AJCC stage Ⅲ/Ⅳ was 8.3%, significantly lower than 91.7% in 40 patients with AJCC stage Ⅰ/Ⅱ, while the positive rate of intensified expression of PERK was 70.0%, significantly higher than 30.0%(P<0.05) in the control; the 1 a, 2 a and 3 a survival rates in 32 patients with cancerous intensified expression of CBX7 were 78.1%, 65.6% and 53.1%, significantly higher than 52.7%, 38.9% and 30.6% (P<0.05) in 36 patients with weak or negative expression, and the 1 a, 2 a and 3 a survival rates in 38 patients with cancerous intensified expression of PERK were 55.3%, 44.7% and 31.6%, significantly lower than 80.0%,63.6% and 53.3% (P<0.05) in 30 patients with weak or negative expression. Conclusion The HCC patients with decreased cancerous expression of CBX7 and intensified expression of PERK might have a poor prognosis after hepatectomy, which should take into consideration in dealing with them in clinical practice.